Determine 1
ACI-12589 distinguished several program atrophy (MSA) from other a-synucleinopathies and nutritious volunteers
A-syn PET tracers could be developed to diagnose a-synuclein pathologies, including Parkinson’s disorder, Lewy Physique Dementia, MSA and other individuals
AC Immune to host a-syn Critical Viewpoint Leader webinar on March 29th
LAUSANNE, Switzerland, March 16, 2022 (Globe NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical firm pioneering precision drugs for neurodegenerative ailments, now declared the to start with non-invasive pictures of pathological alpha-synuclein (a-syn) in human mind and presented constructive scientific evidence-of-concept details for an a-syn positron emission tomography (PET) tracer as an imaging agent to determine MSA individuals. The clinical trial of AC Immune’s wholly owned experimental a-syn PET tracer was performed by the crew of Oskar Hansson MD, PhD, at Lund University and Skåne College Healthcare facility, with the help of a grant from The Michael J. Fox Foundation for Parkinson’s Exploration (MJFF).
The groundbreaking photos of a-syn in the human subjects’ brains ended up offered for the initial time these days at the Ad/PDTM Conference plenary session in Barcelona, Spain, by Oskar Hansson MD, PhD.
Dr. Oskar Hansson, Senior Guide in Neurology at Skåne College Medical center and Professor of Neurology at Lund University, Sweden, mentioned: “This is the to start with time that a PET tracer has reliably detected a-syn aggregates in patients’ brains. The ACI-12589 individual brain scans point out the sign specificity for a-syn in MSA people as opposed to nutritious volunteers and sufferers with other a-synucleinopathies. The outcomes stand for excellent clinical development in the quest to deliver a diagnostic tool for sufferers suffering from MSA and most likely other a-synucleinopathies. This could ultimately permit earlier and extra dependable differentiation for this hard-to-diagnose neurodegenerative condition.”
Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “This to start with scientific validation for an a-syn PET tracer is a transformative action in the direction of attaining our vision for building precision medicines to address neurodegenerative conditions. It was created achievable by the close collaboration in between AC Immune, Skåne University Medical center, Lund College, and the MJFF. We glimpse ahead to continuing the collaboration to develop on these outcomes in MSA and in other a-syn indications, these types of as Parkinson’s disease.”
Jamie Eberling, Ph.D., Senior Vice President of Investigate at MJFF, claimed: “We are energized by the scientific alternatives presented by these results. Selective imaging tracers can make an great distinction in development of new therapies for synucleinopathies such as Parkinson’s ailment. Our Basis has lengthy supported the improvement of these crucial but elusive tools, and we are happy to see progress toward their popular application. As they have for Alzheimer’s sickness, PET tracers for a principal pathological protein would be pivotal in reworking the long run of Parkinson’s analysis and treatment.”
The info will be presented in far more element on Friday in two displays at the peer-reviewed scientific meeting1,2. Derived from AC Immune’s Morphomer® technologies system, ACI-12589 showed target engagement in vivo in alpha-synucleinopathies with a pharmacokinetic and security profile suitable for further improvement as a human mind PET imaging agent. The demo showed that non-invasive PET brain imaging with ACI-12589 properly differentiated MSA from other forms of a-synucleinopathies, like Parkinson’s sickness (PD) and Lewy Physique Dementia (LBD), as effectively as from healthy volunteers.
Especially, the ACI-12589 PET tracer data showed increased distinction and a-syn focus on specificity in participants with MSA. Tracer retention was highest in spots affected by MSA disease procedures, specially cerebellar white issue.
a-syn Critical Opinion Leader webinar on March 29th
In addition to the scientific shows for the duration of Advertisement/PDTM, AC Immune has arranged a KOL webinar on March 29th at 10:00am ET / 4:00pm CET, exactly where Dr. Hansson and AC Immune’s administration will examine ACI-12589 results as perfectly as the significance of biomarkers and precision medication in neurodegenerative ailments. Furthermore, users of the AC Immune management workforce will present an overview of the Company’s medical stage a-syn specific therapeutic and diagnostic candidates.
To sign-up for the webinar, be sure to simply click below. The products from the presentation and a replay of the webinar will be out there on the Activities Website page of AC Immune’s web site next its conclusion.
References
1Capotosti F. Discovery of [18F] ACI-12589, a novel and promising PET-tracer for alpha-synuclein Oral presentation ADPD 2022 International Convention Barcelona, Spain March 18, 2022
2Smith R. Preliminary scans employing [18F] ACI-12589, a novel PET-tracer for alpha-synuclein Oral presentation ADPD 2022 Global Meeting Barcelona, Spain March 18, 2022
About Many Process Atrophy (MSA)
MSA is a unusual, degenerative neurological disorder impacting the body’s involuntary (autonomic) functions, which includes blood tension, respiration, bladder purpose and motor management. MSA causes deterioration and shrinkage (atrophy) of portions of the mind (cerebellum, basal ganglia and brainstem) that regulate internal system capabilities, digestion and motor management. Below a microscope, the weakened brain tissue of persons with MSA displays nerve cells (neurons) that comprise an abnormally substantial quantity of pathological a-syn protein. MSA is tricky to diagnose and is typically bewildered with PD (about 1 in 40 PD sufferers has MSA), and, now, many MSA individuals hardly ever receive a good diagnosis. Though there is overlap, therapeutic treatment tactics are distinct in MSA and PD so, acquiring a accurate diagnosis is pretty crucial.
About AC Immune SA
AC Immune SA is clinical-stage biopharmaceutical business that aims to turn into a worldwide chief in precision medicine for neurodegenerative disorders, which includes Alzheimer’s sickness, Parkinson’s ailment, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technological innovation platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of very first- and best-in-class belongings, which currently functions ten therapeutic and 3 diagnostic candidates, 6 of which are at the moment in scientific trials. AC Immune has a sturdy observe report of securing strategic partnerships with top world wide pharmaceutical providers including Genentech, a member of the Roche Team, Eli Lilly and Firm, and Janssen Prescribed drugs, Inc., resulting in significant non-dilutive funding to progress its proprietary courses and >$3 billion in prospective milestone payments.
SupraAntigen® is a registered trademark of AC Immune SA in the subsequent territories: AU, EU, CH, GB, JP and RU. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, and NO.
For more information and facts, make sure you call:
Ahead on the lookout statements
This press release consists of statements that constitute “forward-wanting statements” within just the this means of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Trade Act of 1934. Forward-looking statements are statements other than historical point and could include things like statements that tackle potential operating, money or business enterprise functionality or AC Immune’s strategies or anticipations. In some scenarios, you can detect these statements by forward-searching phrases this kind of as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other similar terminology. Forward-hunting statements are based on management’s existing anticipations and beliefs and involve important pitfalls and uncertainties that could result in actual final results, developments and company decisions to vary materially from these contemplated by these statements. These threats and uncertainties consist of those described under the captions “Item 3. Critical Information – Risk Factors” and “Item 5. Operating and Financial Overview and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These contain: the impact of Covid-19 on our business, suppliers, people and workforce and any other impression of Covid-19. Ahead-wanting statements converse only as of the date they are made, and AC Immune does not undertake any obligation to update them in light-weight of new info, potential developments or if not, apart from as may well be needed less than relevant legislation. All forward-on the lookout statements are qualified in their entirety by this cautionary statement.
A photograph accompanying this announcement is offered at https://www.globenewswire.com/NewsRoom/AttachmentNg/10e79976-ac90-44b1-83f3-advert7e65204765
